News

Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease a

PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart... Continue Reading

Welcome to the New ASPC Website

Welcome to our new website! We have a brand new look and updated technology in an effort to better serve all our members. We hope that you'll enjoy it as much as we do. In order to get the most out of your member experience, you will need to create a new login. Your previous username and password... Continue Reading

Medtronic announces FDA approval of minimally invasive device to treat hypertension

DUBLIN, Nov. 17, 2023 / PRNewswire / — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Symplicity Spyral™ renal denervation (RDN) system, also known as the Symplicity™... Continue Reading

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclero

The Woodlands, Texas, November 12, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hocanalysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® (sotagliflozin) use in heart failure (HF) and major adverse cardiovascular... Continue Reading

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20%

Bagsværd, Denmark, 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major... Continue Reading

FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option

INDIANAPOLIS, Nov. 8, 2023 / PRNewswire / — The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic... Continue Reading

Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in Patients with HeFH

Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in Patients with HeFH to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 on November 12 at 3:30 p.m. ET; Company to Host Investor Event and Webcast on November 12 at 6:30 p.m. ET BOSTON, Nov. 07, 2023... Continue Reading

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System

Palo Alto, Calif. – November 7, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™... Continue Reading

ASPC partners with Endless Health to support testing attendees’ cholesterol levels at family

Dallas, TX. — The American Society for Preventive Cardiology (ASPC) together with Endless Health will be at the American Academy of Family Physicians’ (AAFP) annual conference – Family Medicine Experience (FMX) – in Chicago, IL October 27-29, 2023 – offering attendees... Continue Reading

2023 Congress Reception Highlights

Since its inception 38 years ago, the American Society for Preventive Cardiology (ASPC) has maintained a robust history of commitment. Established in 1985, the ASPC has consistently prioritized the development of programs aimed at improving both basic and clinical education. Additionally, it has... Continue Reading

Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent;

Basel, July 07, 2023 — Novartis today announced that the U.S. District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity.... Continue Reading

US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults

EAST HANOVER, N.J., July 10, 2023 / PRNewswire / — Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct... Continue Reading